^
    Back
    Association details:
    Biomarker:GPNMB overexpression
    Cancer:Triple Negative Breast Cancer
    Drug:glembatumumab vedotin (CDX-011) (Microtubule inhibitor, GPNMB-targeted antibody-drug conjugate)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Individual Patient Expanded Access-Glembatumumab Vedotin

    Excerpt:
    ...Overexpression of gpNMB in at least one tumor sample as determined by a Sponsor approved laboratory using IHC methods 4....
    Trial ID:
    NCT03067935
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer

    Excerpt:
    The Phase II EMERGE study examined the efficacy of CDX-011 by level of GPNMB expression…. This phase II study investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression….Secondary end point revealed ORR of 12% (10 of 83) versus 12% (five of 41) overall, and 30% (seven of 23) versus 9% (one of 11) for gpNMB overexpression (≥ 25% of tumor cells). Unplanned analysis showed ORR of 18% (five of 28) versus 0% (0 of 11) in patients with triple-negative breast cancer (TNBC), and 40% (four of 10) versus 0% (zero of six) in gpNMB-overexpressing TNBC.
    DOI:
    10.1200/JCO.2014.56.2959
    Trial ID:
    EMERGE